Literature DB >> 26730173

Widespread lymph node recurrence of major duodenal papilla cancer following pancreaticoduodenectomy.

Bai-Sen Li1, Hui Shi1, Min Wen1, Ming-Yong Xiao1, Jian Wang1.   

Abstract

Major duodenal papilla cancer (MDPC) represents the primary type of duodenal cancer, and is typically considered a periampullary carcinoma as most tumors arise in this region. This report describes an extremely rare case involving a patient with rapidly and extensively recurrent MDPC following pancreaticoduodenectomy, who achieved complete response by concurrent image-guided radiation and intravenous oxaliplatin plus oral capecitabine therapies. The patient was a 50-year-old female who was admitted to our hospital 6 wk after resection for MDPC for evaluation of a nontender and enlarged node in the left side of her neck. After clinical work-up, the patient was diagnosed with postoperatively recurrent MDPC with widespread lymph node metastases at the bilateral cervix, mediastinum, abdominal cavity, and retroperitoneal area. She was administered whole field image-guided radiation therapy along with four cycles of the intravenous oxaliplatin plus oral capecitabine regimen. A complete response by positron emission tomography with 18-fluorodeoxyglucose was observed 4 months after treatment. The patient continues to be disease-free 2 years after the diagnosis of recurrence.

Entities:  

Keywords:  Chemoradiotherapy; Complete response; Neoplasm recurrence; Pancreaticoduodenectomy; Periampullary cancer

Mesh:

Substances:

Year:  2015        PMID: 26730173      PMCID: PMC4690191          DOI: 10.3748/wjg.v21.i48.13593

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  23 in total

1.  Significant Reduction of Late Toxicities in Patients With Extremity Sarcoma Treated With Image-Guided Radiation Therapy to a Reduced Target Volume: Results of Radiation Therapy Oncology Group RTOG-0630 Trial.

Authors:  Dian Wang; Qiang Zhang; Burton L Eisenberg; John M Kane; X Allen Li; David Lucas; Ivy A Petersen; Thomas F DeLaney; Carolyn R Freeman; Steven E Finkelstein; Ying J Hitchcock; Manpreet Bedi; Anurag K Singh; George Dundas; David G Kirsch
Journal:  J Clin Oncol       Date:  2015-02-09       Impact factor: 44.544

2.  Image guided radiation therapy (IGRT) technologies for radiation therapy localization and delivery.

Authors:  Jennifer De Los Santos; Richard Popple; Nzhde Agazaryan; John E Bayouth; Jean-Pierre Bissonnette; Mary Kara Bucci; Sonja Dieterich; Lei Dong; Kenneth M Forster; Daniel Indelicato; Katja Langen; Joerg Lehmann; Nina Mayr; Ishmael Parsai; William Salter; Michael Tomblyn; William T C Yuh; Indrin J Chetty
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-05-07       Impact factor: 7.038

3.  Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma.

Authors:  Brian A Boone; Jennifer Steve; Mazen S Zenati; Melissa E Hogg; Aatur D Singhi; David L Bartlett; Amer H Zureikat; Nathan Bahary; Herbert J Zeh
Journal:  Ann Surg Oncol       Date:  2014-08-05       Impact factor: 5.344

4.  Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04.

Authors:  Michael J O'Connell; Linda H Colangelo; Robert W Beart; Nicholas J Petrelli; Carmen J Allegra; Saima Sharif; Henry C Pitot; Anthony F Shields; Jerome C Landry; David P Ryan; David S Parda; Mohammed Mohiuddin; Amit Arora; Lisa S Evans; Nathan Bahary; Gamini S Soori; Janice Eakle; John M Robertson; Dennis F Moore; Michael R Mullane; Benjamin T Marchello; Patrick J Ward; Timothy F Wozniak; Mark S Roh; Greg Yothers; Norman Wolmark
Journal:  J Clin Oncol       Date:  2014-05-05       Impact factor: 44.544

5.  CA 19-9 as a marker in addition to CEA to monitor colorectal cancer.

Authors:  Jolanda Stiksma; Diana C Grootendorst; Peter Willem G van der Linden
Journal:  Clin Colorectal Cancer       Date:  2014-09-18       Impact factor: 4.481

6.  What are the latest pharmacotherapy options for small bowel adenocarcinoma?

Authors:  Marie Lourdes Ynson; Frank Senatore; Constantin A Dasanu
Journal:  Expert Opin Pharmacother       Date:  2014-03-04       Impact factor: 3.889

7.  Adenocarcinoma of the duodenum: importance of accurate lymph node staging and similarity in outcome to gastric cancer.

Authors:  Abeezar I Sarela; Murray F Brennan; Martin S Karpeh; David Klimstra; Kevin C P Conlon
Journal:  Ann Surg Oncol       Date:  2004-03-15       Impact factor: 5.344

8.  Pancreaticoduodenectomy: a 20-year experience in 516 patients.

Authors:  C Max Schmidt; Emilie S Powell; Constantin T Yiannoutsos; Thomas J Howard; Eric A Wiebke; Chad A Wiesenauer; Joel A Baumgardner; Oscar W Cummings; Lewis E Jacobson; Thomas A Broadie; David F Canal; Robert J Goulet; Eardie A Curie; Higinia Cardenes; John M Watkins; Patrick J Loehrer; Keith D Lillemoe; James A Madura
Journal:  Arch Surg       Date:  2004-07

9.  Does the extent of resection impact survival for duodenal adenocarcinoma? Analysis of 1,611 cases.

Authors:  Jordan M Cloyd; Jeffrey A Norton; Brendan C Visser; George A Poultsides
Journal:  Ann Surg Oncol       Date:  2014-08-27       Impact factor: 5.344

10.  Image-guided radiation therapy using surgical clips for localization of colonic metastasis from thyroid cancer.

Authors:  Alvin Szeto; Lee Chin; Patrick Whelan; Jennifer Wilson; Justin Lee
Journal:  Radiat Oncol       Date:  2014-12-24       Impact factor: 3.481

View more
  1 in total

1.  The association between Helicobacter pylori and chronic otitis media with effusion.

Authors:  Ahmed Taha; Jacob Pitaro; Tsilia Lazarovitch; Limor Muallem-Kalmovich; Yael Garti; Haim Gavriel
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-09-30       Impact factor: 3.236

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.